Vaxart's Second-Generation Norovirus Vaccine Shows Stronger Immune Response in Phase 1 Study

Vaxart, Inc. (NASDAQ: VXRT) shared encouraging new results for its next-generation norovirus vaccine, showing it produced much stronger immune responses than its earlier version in a Phase 1 study.

The clinical trial involved 60 healthy volunteers who received either the original vaccine or an improved, second-generation version. The newer version significantly boosted important antibody responses, including a 141% increase in GI.1 norovirus antibodies and a 94% rise in GII.4 antibodies. These types of antibodies help the body fight off norovirus infections.

In simple terms, these results suggest that the updated vaccine triggered a much stronger immune reaction, which could help better protect against norovirus, a common stomach virus that leads to vomiting, diarrhea, and lost productivity.

All doses of the updated vaccine were safe and well tolerated, with no serious side effects linked to the vaccine.

Vaxart's Chief Scientific Officer, Dr. Sean Tucker, said these findings prove the new design works as intended, while CEO Steven Lo emphasized that norovirus has no approved vaccine despite causing 685 million infections globally each year.

Following these positive early results, Vaxart plans to launch a larger study in the second half of 2025 and aims to begin a late-stage Phase 3 trial as early as 2026.

Norovirus is a major cause of stomach-related illness in the U.S. and worldwide, costing an estimated $60 billion each year. Vaxart's vaccine is an oral pill rather than a shot, making it easier to distribute and take.

The post Vaxart's Second-Generation Norovirus Vaccine Shows Stronger Immune Response in Phase 1 Study appeared first on PRISM MarketView.

COMTEX_466284643/2927/2025-06-11T15:31:29